Scribe Therapeutics Closes Series B Round With $100M To Target Gene Editing
Crunchbase News
|
March 31, 2021
X min read
Crunchbase News
|
March 31, 2021
Share on Social
More like this
News
Scribe Therapeutics Highlights Latest Data on Lp(a)-Lowering Therapy and Novel AI Platform for Next-Generation CRISPR-Based Therapeutics at Two Premier Conferences
September 9, 2025
Read Now
Press
Scribe Therapeutics Highlights Latest Data on Lp(a)-Lowering Therapy and Novel AI Platform for Next-Generation CRISPR-Based Therapeutics at Two Premier Conferences
September 9, 2025
Read Now
News
Scribe Therapeutics to Demonstrate Scientific and Corporate Leadership at Upcoming Conferences
August 25, 2025
Read Now
Press
Scribe Therapeutics to Demonstrate Scientific and Corporate Leadership at Upcoming Conferences
August 25, 2025
Read Now
News
Scribe Therapeutics Reports Positive Preclinical Data on its Novel CRISPR Technologies at the 2025 EAS Congress and ASGCT Annual Meeting
May 22, 2025
Read Now
Press
Scribe Therapeutics Reports Positive Preclinical Data on its Novel CRISPR Technologies at the 2025 EAS Congress and ASGCT Annual Meeting
May 22, 2025
Read Now
